Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIVELLA vs LOPURIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
LOPURIN is a brand name for allopurinol, a xanthine oxidase inhibitor. It reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Treatment of moderate to severe vasomotor symptoms associated with menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause,Prevention of postmenopausal osteoporosis
Gout prophylaxis,Management of hyperuricemia in patients with cancer undergoing chemotherapy,Prevention of recurrent calcium oxalate calculi in patients with hyperuricuria
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
200-600 mg orally once daily, typically starting at 300 mg/day and adjusting based on serum urate levels.
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
Allopurinol: 1-2 hours; oxypurinol: 18-30 hours (renal function dependent). Accumulation in renal failure; half-life of oxypurinol may exceed 100 hours in ESRD.
Estradiol is metabolized primarily in the liver via CYP3A4 and other CYPs, as well as by 17β-hydroxysteroid dehydrogenase and sulfotransferases. Norethindrone acetate is metabolized in the liver, primarily via reduction and conjugation, with CYP3A4 involved in some oxidative metabolism.
Primarily hepatic via aldehyde oxidase to oxypurinol (alloxanthine), which is also active; minor metabolism by xanthine oxidase.
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Renal (primarily as unchanged drug and active metabolite oxypurinol): ~70% urinary excretion; remainder biliary/fecal. Dose adjustment required in renal impairment.
Estradiol is ∼98% bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone is ∼95–97% bound to SHBG and albumin.
Allopurinol: <1%; oxypurinol: ~20% (primarily to albumin). Negligible displacement interactions.
Estradiol has an apparent volume of distribution (Vd) of approximately 1.2 L/kg, indicating extensive distribution into tissues. Norethindrone has a Vd of approximately 3–5 L/kg, indicating wide distribution.
Allopurinol: ~1.6 L/kg; oxypurinol: ~0.6 L/kg. Indicates extensive tissue distribution, including renal and hepatic tissues.
Transdermal estradiol has a bioavailability of approximately 10% relative to oral administration due to avoidance of first-pass metabolism. Oral norethindrone acetate has a bioavailability of approximately 50–60%.
Oral allopurinol: ~80% (mean); conversion to oxypurinol reduces systemic availability of parent drug. Food delays absorption but does not affect extent.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated.
For GFR 10-20 m L/min: 200 mg/day; GFR <10 m L/min: 100 mg/day or avoid use; consider alternative in severe impairment.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use caution and monitor; no specific dose adjustment established.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce by 75%.
Not indicated for use in pediatric patients; safety and efficacy not established.
Children 6-10 years: 100 mg orally once daily; 11-16 years: 200-300 mg orally once daily; adjust based on serum urate.
Start with the lowest effective dose; monitor for thromboembolic events and cognitive effects. No specific dose adjustment required, but consider age-related renal and hepatic decline.
Start at lower end of dosing range (100-200 mg/day) due to age-related renal decline; monitor renal function and urate levels.
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events, breast cancer, and probable dementia with estrogen plus progestin therapy. Actively monitor for these events.
No FDA black box warning.
Cardiovascular disorders: Increased risks of stroke, myocardial infarction, and venous thromboembolism (VTE).,Malignancy: Increased risk of breast cancer, endometrial cancer, and ovarian cancer.,Probable dementia: Increased risk in women aged 65 years or older.,Gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, and hereditary angioedema.,Retinal thrombosis: Discontinue if sudden vision loss occurs.,Laboratory tests: May alter thyroid function tests, coagulation tests, and glucose tolerance.
Hypersensitivity syndrome (DRESS) may occur; discontinue at first sign of rash,Acute gout flares may occur upon initiation; prophylactic colchicine or NSAIDs recommended,Renal impairment requires dose adjustment; increase doses cautiously,Monitor liver function; hepatotoxicity reported,Bone marrow suppression (leukopenia, thrombocytopenia) may occur,Anticoagulant effect of warfarin may be enhanced
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Current or recent (within 1 year) VTE or ATE,Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency; factor V Leiden mutation),Active or past history of arterial thromboembolic disease (e.g., stroke, MI),Known liver impairment or disease,Known or suspected pregnancy,Hypersensitivity to any component of the product
Hypersensitivity to allopurinol or any component,Concurrent use with azathioprine or mercaptopurine unless dose reduction is implemented
Grapefruit juice may increase estrogen levels by inhibiting CYP3A4; avoid excessive consumption. High-fat meals can increase absorption of oral estrogens; take consistently with or without food to maintain steady levels.
Avoid high-purine foods (organ meats, sardines, anchovies, shellfish, red meat). Limit alcohol intake, particularly beer and spirits. Maintain adequate hydration. No significant food-drug interactions reported.
Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the second and third trimesters is contraindicated due to risk of fetal genital abnormalities and potential long-term neurodevelopmental effects. Avoid in pregnancy.
FDA Pregnancy Category D. First trimester: risk of congenital heart defects, cleft palate, and hypospadias based on animal studies and limited human data. Second and third trimesters: risk of fetal renal dysfunction, oligohydramnios, and neonatal renal impairment due to fetal renin-angiotensin system suppression.
Estradiol and norethindrone acetate are excreted into breast milk. Estradiol M/P ratio approximately 0.5; norethindrone M/P ratio approximately 0.4. May reduce milk production and alter composition. Use during breastfeeding is not recommended.
Small amounts of LOPURIN are excreted in breast milk. M/P ratio is approximately 0.2. The American Academy of Pediatrics considers the drug compatible with breastfeeding, but caution is advised due to potential for infant renal effects. Monitor infant for hypotension and renal function.
Not applicable; contraindicated in pregnancy.
Increased plasma volume during pregnancy may reduce concentrations; dose adjustments are not routinely recommended due to variable pharmacokinetics. However, if blood pressure control is inadequate, consider increasing the dose under close monitoring. Postpartum, reduce dose to prepregnancy level to avoid hypotension.
For patients with an intact uterus, estrogen must be combined with a progestogen (norethindrone acetate) to prevent endometrial hyperplasia. Initiate at the lowest effective dose for the shortest duration. Avoid in women with active thromboembolic disease, known or suspected breast cancer, or undiagnosed abnormal genital bleeding. Consider transdermal route if oral absorption is compromised or for migraine with aura.
Allopurinol is a xanthine oxidase inhibitor. Initiate at low dose (100 mg/day) and titrate to reduce risk of gout flares. Monitor for hypersensitivity reactions, especially in renal impairment. Doses must be adjusted for renal function (Cr Cl <60 m L/min). Do not use with azathioprine or 6-mercaptopurine without dose reduction of cytotoxic agents. Avoid restarting after severe hypersensitivity.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, breast lumps, or symptoms of blood clots (e.g., leg pain, chest pain, sudden shortness of breath, vision changes) immediately.,Smoking increases the risk of cardiovascular side effects, especially in women over 35; avoid smoking while on this therapy.,This medication does not protect against sexually transmitted infections or HIV.,Regular medical check-ups, including breast exams and mammograms, are essential during therapy.
Take after meals to reduce GI upset.,Drink plenty of fluids (2-3 liters/day) to prevent kidney stones.,Report any rash, itching, or swelling immediately as these may signal a serious allergic reaction.,Do not stop medication abruptly; gout flares may occur during early treatment.,Avoid alcohol, especially beer, as it can increase uric acid levels.,Keep regular appointments for blood tests to monitor uric acid and kidney function.
No interactions on record
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"The combination of allopurinol and captopril increases the risk of hypersensitivity reactions, including Stevens-Johnson syndrome and angioedema, due to a pharmacodynamic interaction that potentiates immune-mediated adverse effects. This is particularly concerning in patients with renal impairment, where both drugs may accumulate, and can lead to severe cutaneous adverse reactions or hematologic toxicities."
"Allopurinol inhibits xanthine oxidase, an enzyme involved in the catabolism of purine analogs. Tegafur is a prodrug of 5-fluorouracil and is metabolized via the same pathway. Coadministration of allopurinol may reduce the conversion of tegafur to its active metabolite, thereby decreasing the therapeutic efficacy of tegafur. This can lead to suboptimal antineoplastic effect and potential treatment failure."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIVELLA vs LOPURIN, answered by our medical review team.
ACTIVELLA is a Estrogen/Progestin Combination that works by Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.. LOPURIN is a Xanthine oxidase inhibitor that works by LOPURIN is a brand name for allopurinol, a xanthine oxidase inhibitor. It reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIVELLA and LOPURIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIVELLA is: One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.. The standard adult dose of LOPURIN is: 200-600 mg orally once daily, typically starting at 300 mg/day and adjusting based on serum urate levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIVELLA and LOPURIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIVELLA is classified as Category C. Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the s. LOPURIN is classified as Category C. FDA Pregnancy Category D. First trimester: risk of congenital heart defects, cleft palate, and hypospadias based on animal studies and limited human data. Second and third trimeste. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.